Item 5.07. Submission of Matters to a Vote of Security Holders.

At the annual meeting (the "Annual Meeting") of stockholders of NeuroOne Medical Technologies Corporation (the "Company") on May 31, 2022, stockholders (i) elected one Class II director to the Company's Board of Directors to serve a three-year term until the 2025 annual meeting of stockholders, and (ii) ratified the appointment of Baker Tilly U.S., LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2022. Proposals are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2022.

A total of 9,491,751 shares of the Company's common stock were present at the meeting in person or by proxy, which represents approximately 58.62% of the shares of common stock outstanding as of the record date for the Annual Meeting.

The results of the voting are shown below:

Proposal 1-Election of Director




Class I Nominee   Votes For   Votes Withheld   Broker Non-Votes
David Rosa        4,552,178      411,044          4,528,529

Proposal 2-Ratification of Appointment of Independent Registered Public Accounting Firm





Votes For   Votes Against   Votes Abstain
9,421,086      44,729          25,936


Item 8.01 Other Events.

On June 2, 2022, NeuroOne Medical Technologies Corporation issued a press release providing a copy of the Annual Letter to Shareholders. A copy of this press release is filed herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit No.     Description
99.1            Press Release, dated June 2, 2022
104           Cover Page Interactive Data File (embedded with Inline XBRL document).




                                       1

© Edgar Online, source Glimpses